WuXi AppTec Increases Interim Dividend to RMB 1.51 Billion
WuXi AppTec, a global pharmaceutical CRDMO, announced its 2026 interim cash dividend will total RMB 1.51 billion. The increase continues the company's strategy of rewarding shareholders.
SHANGHAI – WuXi AppTec Co., Ltd. has announced that its 2026 interim cash dividend will amount to RMB 1.51 billion (approximately $210 million). The company stated the move is part of its ongoing commitment to return value to shareholders.
The interim dividend represents an increase from previous distributions, reflecting the company's financial performance. WuXi AppTec provides services across the drug development and manufacturing lifecycle for the global pharmaceutical, biotech, and health technology industries.
This dividend announcement follows the company's reporting of its second-quarter financial results. Specific payment dates and details will be communicated separately.
WuXi AppTec operates as a Contract Research, Development, and Manufacturing Organization (CRDMO), offering integrated services to clients worldwide.